Roche acquires Inflazome to gain control over inflammatory treatments
By Nikita Chaurasia  Date: 2020-09-22

Roche acquires Inflazome to gain control over inflammatory treatments

In a recent turn of events, Swiss healthcare giant, F. Hoffmann-La Roche AG has reportedly acquired an Irish biotech firm Inflazome Ltd. for approximately USD 451 million (€380 million).

As per the agreement, Roche will acquire complete rights to Inflazome’s portfolio of oral NLRP3 inflammasome inhibitors, which are currently being developed for treating conditions such as Parkinson’s and other diseases, sources claimed.

Since its inception in 2016, Inflazome has been gaining worldwide recognition owing to its expertise in inflammasome inhibitors.  The firm is currently developing an oral NLRP3 inflammasome inhibitor in order to meet the unmet demands for various inflammatory diseases. In fact, the company claims the inhibitor has already completed Phase 1 human trails as well as various early-stage programmes.

Inflazome is also developing drugs which targets inflammasomes associated with arthritis, asthma, Alzheimer’s, Parkinson’s, and bowel disease as well as other chronic inflammatory conditions, cited sources with relevant information.

Matt Cooper, CEO at Inflazome was reported saying that the company is thrilled to enter a joint venture agreement with one of the prominent pharmaceutical giant Roche. He added that the acquisition will allow Inflazome to quickly and effectively develop its products in order to aid patients with debilitating diseases.

It is to be noted that earlier in July, Roche and its subsidiary Genentech Inc. entered a joint venture agreement with UCB, a Belgian company to produce and commercialize an antibody drug UCB0107 for treating Alzheimer’s disease

Several other pharmaceutical companies are also working on similar drug developments. In fact, IFM Therapeutics sold its subsidiaries with NLRP3 assets to Novartis International AG and Bristol Myers Squibb (BMS).

Source credits –

https://www.fiercebiotech.com/biotech/roche-pays-eu380m-for-nlrp3-biotech-inflazome-claiming-a-leading-position-hot-field

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Nokia, Greener Acres partner to boost smart city development in Canada
Nokia, Greener Acres partner to boost smart city development in Canada
By Nikita Chaurasia

According to reliable sources, Finnish multinational telecommunication, consumer electronics and information technology company Nokia Corp. has reportedly signed an agreement with Greener Acres Canada Inc. to collectively develop and upgrade the util...

OneOncology launches OneR to accelerate clinical research programs
OneOncology launches OneR to accelerate clinical research programs
By Nikita Chaurasia

In recent developments, Tennessee-based oncology medical service provider OneOncology Inc., has reportedly announced the establishment of a newly formed subsidiary named OneR (OneOncology Research Network). Sources close to the matter claimed that O...

Helix Technologies, MOR Analytics to unite under new banner Forian Inc.
Helix Technologies, MOR Analytics to unite under new banner Forian Inc.
By Nikita Chaurasia

According to reliable sources, U.S.-based critical infrastructure service provider of cannabis industry, Helix Technologies Inc. has reportedly announced a strategic merger with Medical Outcomes Research Analytics LLC (MOR Analytics) to become wholly...

German software firm Celonis launches the market’s first EMS
German software firm Celonis launches the market’s first EMS
By Nikita Chaurasia

Celonis, a German leader in AI-enhanced Process Excellence and Process Mining, has reportedly launched the first EMS (Execution Management System) of the industry. The company has specifically developed the EMS to remove system complexity, which is t...

Informatica adds advanced capabilities to enterprise cloud platform
Informatica adds advanced capabilities to enterprise cloud platform
By Nikita Chaurasia

Informatica, a leading US based enterprise cloud data management firm, has reportedly rolled out new, enhanced capabilities that are designed to help its clients become cloud-native, cloud-first in the COVID-19 pandemic. IDC (International Data Corpo...